Zobrazeno 1 - 10
of 180
pro vyhledávání: '"Singavi A"'
Autor:
Xiong, Donghai, Wang, Yian, Singavi, Arun K., Mackinnon, Alexander C., George, Ben, You, Ming
Publikováno v:
In iScience 30 November 2018 9:258-277
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Sarabjot Pabla, Jeffrey M. Conroy, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jacob Hagen, Vincent Giamo, Jonathan Andreas, Felicia L. Lenzo, Wang Yirong, Grace K. Dy, Edwin Yau, Amy Early, Hongbin Chen, Wiam Bshara, Katherine G. Madden, Keisuke Shirai, Konstantin Dragnev, Laura J. Tafe, Daniele Marin, Jason Zhu, Jeff Clarke, Matthew Labriola, Shannon McCall, Tian Zhang, Matthew Zibelman, Pooja Ghatalia, Isabel Araujo-Fernandez, Arun Singavi, Ben George, Andrew Craig MacKinnon, Jonathan Thompson, Rajbir Singh, Robin Jacob, Lynn Dressler, Mark Steciuk, Oliver Binns, Deepa Kasuganti, Neel Shah, Marc Ernstoff, Kunle Odunsi, Razelle Kurzrock, Mark Gardner, Lorenzo Galluzzi, Carl Morrison
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Abstract Background Resistance to immune checkpoint inhibitors (ICIs) has been linked to local immunosuppression independent of major ICI targets (e.g., PD-1). Clinical experience with response prediction based on PD-L1 expression suggests that other
Externí odkaz:
https://doaj.org/article/4f4efc20d258452fa94c335442c051f9
Autor:
Jeffrey M. Conroy, Sarabjot Pabla, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jonathan Andreas, Vincent Giamo, Yirong Wang, Felicia L. Lenzo, Wiam Bshara, Maya Khalil, Grace K. Dy, Katherine G. Madden, Keisuke Shirai, Konstantin Dragnev, Laura J. Tafe, Jason Zhu, Matthew Labriola, Daniele Marin, Shannon J. McCall, Jeffrey Clarke, Daniel J. George, Tian Zhang, Matthew Zibelman, Pooja Ghatalia, Isabel Araujo-Fernandez, Luis de la Cruz-Merino, Arun Singavi, Ben George, Alexander C. MacKinnon, Jonathan Thompson, Rajbir Singh, Robin Jacob, Deepa Kasuganti, Neel Shah, Roger Day, Lorenzo Galluzzi, Mark Gardner, Carl Morrison
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Abstract Background PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at least 4 different assays and antibodies used for PD-L1 IHC, each develope
Externí odkaz:
https://doaj.org/article/ba0a2468e04d487e8d2b8fe0e2e078e6
Publikováno v:
iScience, Vol 9, Iss , Pp 258-277 (2018)
Summary: Although PD-1-blocking immunotherapies demonstrate significant therapeutic promise, a subset of the patients could develop hyperprogressive disease (HPD) with accelerated tumor growth after anti-PD1 immunotherapy. To elucidate the underlying
Externí odkaz:
https://doaj.org/article/d63d4257d7cb49a2bbed4447c65e8f9f
Autor:
Anthony R. Mato, Amy A. Kirkwood, Anna Schuh, Neil Bailey, Andrea Sitlinger, Laurie Pearson, Sivraj Muralikrishnan, Andre Goy, Ryan Jacobs, Annalynn M. Williams, John M. Pagel, Charlene Kabel, Hannah Morse, Colleen Dorsey, Joanna Rhodes, Allison M. Winter, Hande H. Tuncer, Chaitra S. Ujjani, Mazyar Shadman, Alan P. Skarbnik, Paul M. Barr, Catherine C. Coombs, Arun K. Singavi, Nicole Lamanna, Bruce D. Cheson, Maryam Yazdy, Frederick Lansigan, Nirav N. Shah, Brian T. Hill, Chadi Nabhan, Stephen J. Schuster, John N. Allan, Danielle M. Brander, Toby A. Eyre, Christopher P. Fox, Lindsey E. Roeker
Purpose:Clinical trials of venetoclax reported negligible rates of clinical tumor lysis syndrome (TLS) in patients with chronic lymphocytic leukemia (CLL) when using an extended dose escalation schedule. We aimed to understand TLS prophylaxis, rates
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1141a6ec125abdac6fd3f47dbf2ea5e3
https://doi.org/10.1158/1078-0432.c.6528248
https://doi.org/10.1158/1078-0432.c.6528248
Autor:
Anthony R. Mato, Amy A. Kirkwood, Anna Schuh, Neil Bailey, Andrea Sitlinger, Laurie Pearson, Sivraj Muralikrishnan, Andre Goy, Ryan Jacobs, Annalynn M. Williams, John M. Pagel, Charlene Kabel, Hannah Morse, Colleen Dorsey, Joanna Rhodes, Allison M. Winter, Hande H. Tuncer, Chaitra S. Ujjani, Mazyar Shadman, Alan P. Skarbnik, Paul M. Barr, Catherine C. Coombs, Arun K. Singavi, Nicole Lamanna, Bruce D. Cheson, Maryam Yazdy, Frederick Lansigan, Nirav N. Shah, Brian T. Hill, Chadi Nabhan, Stephen J. Schuster, John N. Allan, Danielle M. Brander, Toby A. Eyre, Christopher P. Fox, Lindsey E. Roeker
Supplemental Table 1 and Supplemental Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07586467baaefab6a3670db6e220430f
https://doi.org/10.1158/1078-0432.22472513
https://doi.org/10.1158/1078-0432.22472513
Autor:
Ariel Kleman, Arun K Singavi, Lauren Pommert, Angela Joy Mathison, Parameswaran Hari, Binod Dhakal, Meera Mohan, Siegfried Janz, Jennifer Mary Knight, Mithun Vinod Shah, Carolina Schinke, Robert Thomas Burns, George Francis Steinhardt, Sridhar Rao, Karen-Sue Barker Carlson
Publikováno v:
Blood Advances.
Autor:
Anthony R. Mato, Meghan Thompson, John N. Allan, Danielle M. Brander, John M. Pagel, Chaitra S. Ujjani, Brian T. Hill, Nicole Lamanna, Frederick Lansigan, Ryan Jacobs, Mazyar Shadman, Alan P. Skarbnik, Jeffrey J. Pu, Paul M. Barr, Alison R. Sehgal, Bruce D. Cheson, Clive S. Zent, Hande H. Tuncer, Stephen J. Schuster, Peter V. Pickens, Nirav N. Shah, Andre Goy, Allison M. Winter, Christine Garcia, Kaitlin Kennard, Krista Isaac, Colleen Dorsey, Lisa M. Gashonia, Arun K. Singavi, Lindsey E. Roeker, Andrew Zelenetz, Annalynn Williams, Christina Howlett, Hanna Weissbrot, Naveed Ali, Sirin Khajavian, Andrea Sitlinger, Eve Tranchito, Joanna Rhodes, Joshua Felsenfeld, Neil Bailey, Bhavisha Patel, Timothy F. Burns, Melissa Yacur, Mansi Malhotra, Jakub Svoboda, Richard R. Furman, Chadi Nabhan
Publikováno v:
Haematologica, Vol 103, Iss 9 (2018)
Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. We conducted a multicenter retrospective cohort analysis of patients with chronic lymphocytic leukemia
Externí odkaz:
https://doaj.org/article/cf0cc2d2d3144e71a74d686f011301aa
Autor:
Landsburg, Daniel J., Falkiewicz, Marissa K., Maly, Joseph, Blum, Kristie A., Howlett, Christina, Feldman, Tatyana, Mato, Anthony R., Hill, Brian T., Li, Shaoying, Medeiros, L. Jeffrey, Torka, Pallawi, Hernandez-Ilizaliturri, Francisco, Reddy, Nishitha M., Singavi, Arun, Fenske, Timothy S., Chavez, Julio C., Kaplan, Jason B., Behdad, Amir, Petrich, Adam M., Bast, Martin A., Vose, Julie M., Olszewski, Adam J., Costa, Cristiana, Lansigan, Frederick, Gerson, James N., Barta, Stefan K., Calzada, Oscar, Cohen, Jonathon B., Lue, Jennifer K., Amengual, Jennifer E., Rivera, Xavier, Persky, Daniel O., Peace, David J., Nathan, Sunita, Cassaday, Ryan D.
PurposePatients with double-hit lymphoma (DHL) rarely achieve long-term survival following disease relapse. Some patients with DHL undergo consolidative autologous stem-cell transplantation (autoSCT) to reduce the risk of relapse, although the benefi
Externí odkaz:
http://hdl.handle.net/10150/624897
http://arizona.openrepository.com/arizona/handle/10150/624897
http://arizona.openrepository.com/arizona/handle/10150/624897